SB
MACK

Suntrust Banks’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Suntrust Banks’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,790
Closed -$70K – 1821
2014
Q1 		$70K Hold
1,790
– – ﹤0.01% 1868
2013
Q4 		$74K Hold
1,790
– – ﹤0.01% 1797
2013
Q3 		$52K Buy
+1,790
New +$62.6K ﹤0.01% 1788

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Suntrust Banks's MACK Position: Q2 2014 in Review

Suntrust Banks sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2014, closing a stake of 1,790 shares — an estimated $70K sold.

Suntrust Banks first reported a position in MACK in Q3 2013 and held it in 3 quarters. The position peaked at $74K in Q4 2013. 121 funds tracked by Wall St. Rank hold MACK as of Q2 2014.

  • Suntrust Banks reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Suntrust Banks sold 1,790 Merrimack Pharmaceuticals, Inc. shares in Q2 2014, an estimated $70K.
  • Suntrust Banks first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 3 quarters.
  • Suntrust Banks's Merrimack Pharmaceuticals, Inc. position peaked at $74K in Q4 2013.
  • 121 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2014.

Based on Suntrust Banks's 13F filing for Q2 2014, filed 14 Aug 2014.